Cure My Disease

Don't miss your cure!

 Log in / Sign up

A virtual Walk-Through of radiotherapy may calm cancer Patients' nerves

NCT ID NCT07721246

Symptom relief Sponsor: University Medical Center Goettingen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Aug 12, 2026 · Updated 3 times

Summary

Many cancer patients feel anxious before radiotherapy, partly due to unfamiliar equipment and procedures. This trial tests whether adding a simulation-based education session — a virtual preview of the treatment environment — before standard education can reduce that anxiety and improve quality of life. Around 120 adults starting radiotherapy for the first time will be randomly assigned to receive either standard education alone or standard education plus the simulation session. Researchers will compare changes in anxiety and well-being between the two groups.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
simulation-based patient education session
What this could lead to
If effective, this low-cost educational approach could become a standard tool to ease anxiety and improve well-being for cancer patients starting radiotherapy.
What could go wrong
This is a small, early-phase trial, so results may not apply broadly. The intervention may not reduce anxiety more than standard education alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 144 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2028

An estimate. Start dates often move.

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older * Histologically or cytologically confirmed malignant tumor disease * Stage I - III (UICC TNM classification) * ECOG performance status ≤ 2 * Curative-intent external beam radiotherapy regimen with at least 5 fractions * First course of radiotherapy * Able to independently operate the electronic data collection instrument * Written informed consent after study information * Sufficient German language proficiency to read and complete the study questionnaires independently and without translation assistance Exclusion Criteria: * Lack of capacity to provide informed consent * Pregnancy or breastfeeding * Stereotactic radiotherapy * Emergency treatment indication * Acute suicidality, acute psychosis, or other acute psychiatric disorder * Initiation of or dose change in psychotropic medication within 4 weeks before baseline (T0) * Cognitive impairment that precludes independent completion of the questionnaires * Visual or auditory impairment that prevents perception of the on-screen or audio content despite available aids

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anxiety are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anxiety anxiety disorder cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anxiety Neoplasms Patient education Psychosocial effects of cancer and its treatment Radiotherapy-related anxiety

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Radiotherapy and Radiation Oncology, University Medical Center Goettingen

    Göttingen, Lower Saxony, 37075, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.